Abstract
The variability associated with the estimation of the pharmacokinetic and pharmacodynamic parameters of a population has traditionally been described using simple statistical terms such as the mean and standard deviation. Other sources of variability exist within the population, such as the quantitative relationship of the parameter to individual physiology (such as weight, age, kidney function), the magnitude of the intersubject variability across the population and the magnitude of the residual deviations between the predicted and observed drug concentrations within a subject1,2.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sheiner LB, Grasela TH. An introduction to mixed effects modeling: concepts, definitions and justification. J Pharmacokinetic Biopharm 1991; 19: 11S–23S.
Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984;15: 153–71.
Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981;9: 635–651.
Beal SL, Sheiner LB. Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab Rev 1984;15: 173–93.
Beal SL and Sheiner LB. NONMEM Users guides, NONMEM Project Group, UCSF, San Francisco, CA, 1992.
In vitro-in vivo correlations. Pharmacopeial Forum USP 1993;19:5374-9.
‘Draft guidance for industry: modified release solid dosage forms; scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation. U.S. Department of Health and Human Services, Food and Drug Administration, July 1996.
Leeson LJ. In vitro/in vivo correlations. Drug Info J 1995;29: 903–15.
Hussein Z, Freidman M. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation. Pharm Res 1990;7: 1167–71.
Hyashi T, Ogura T, Takagishi Y. New evaluation method for in vitro/in vivo correlation of enteric coated multiple unit dosage forms. Pharm Res 1995;12: 1333–7.
Gillespie WR, Veng-Pedersen P. A polyexponential deconvolution method. Evaluation of the “gastrointestinal bioavailability” and mean in vivo dissolution time of some ibuprofen dosage forms. J Pharmacokinet Biopharm 1985;13: 289–307.
Gillespie WR. PCDCON: Deconvolution for pharmacokinetic applications. University of Texas at Austin, Austin TX. 1992
ADAPT II. D’Argenio D. Biomedical Simulations Resource, USC, CA.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Plenum Press, New York
About this chapter
Cite this chapter
Bigora, S. et al. (1997). Use of Nonlinear Mixed Effects Modelling in the Development of in Vitro-in Vivo Correlations. In: Young, D., Devane, J.G., Butler, J. (eds) In Vitro-in Vivo Correlations. Advances in Experimental Medicine and Biology, vol 423. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-6036-0_19
Download citation
DOI: https://doi.org/10.1007/978-1-4684-6036-0_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-6038-4
Online ISBN: 978-1-4684-6036-0
eBook Packages: Springer Book Archive